$CBDL CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Columbian Company
accessnewswire.com
New manufacturing deal positions CBDL to tap into the $4.9 billion Latin American CBD market, unlocking major revenue growth and accelerating international expansion.
SCOTTSDALE, ARIZONA / ACCESS Newswire / April 29, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leading innovator in the cannabidiol (CBD) wellness industry, is proud to announce a major new manufacturing partnership with Thallos, a premier South American company headquartered in Colombia. Under this agreement, CBDL will take full control of the production, packaging, and labeling of a specialized line of high-potency CBD products exclusively for Thallos - a strategic move expected to significantly boost CBDL's global revenue streams.
CBDL is set to manufacture Thallos' flagship offerings, including a 2,000mg Pain Cream Salve available in both Mint and Cinnamon varieties, along with a 2,000mg CBD Tincture. These products will be produced entirely in-house at CBDL's state-of-the-art facilities, allowing the company to maintain strict quality assurance while maximizing manufacturing efficiencies.
With South America's CBD market projected to surpass $4.9 billion by 2028 and Colombia emerging as a major player, the opportunity is enormous. Due to current U.S. tariff impacts and regulatory hurdles, Colombian companies like Thallos face increasing challenges importing CBD goods. CBDL's ability to offer domestic U.S. manufacturing and distribution provides a turnkey solution, giving Thallos a competitive edge while delivering substantial new revenue for CBDL.
"This partnership is a game-changer for CBDL," said Lisa Nelson, CEO of CBD Life Sciences Inc. "By strategically positioning ourselves as the manufacturing engine for a growing South American brand, we're opening the door to scalable, recurring revenue and strengthening our position as a dominant force in the global CBD supply chain."
In addition to strengthening its financial foundation, this new international venture demonstrates CBD Life Sciences Inc.'s continued commitment to innovation, growth, and global leadership. CBDL is now uniquely positioned to leverage international partnerships, expanding its footprint into some of the fastest-growing markets in the world and setting the stage for record-breaking performance in 2025 and beyond. |
